IL-3 inhibitor is developed by the Molecular Immunology research group led by Matthias Mack at the University of Regensburg.
IL-3 is a growth factor produced by activated T cells which stimulates growth and differentiation of monocytes, basophils and other leukocyte populations from the bone marrow in an immune response.
IL-3 plays a role in the onset of rheumatoid arthritis (RA).
Therapy with an antibody-based IL-3 inhibitor, either in early stages or during flares and exacerbations provides a new class of treatment for patients suffering from RA.
The agreement was closed with Bayerische Patentallianz, the central patent and marketing agency of 28 Bavarian universities and universities of applied sciences.